Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test.

Alice Y GuhScott FridkinDana GoodenoughLisa G WinstonHelen JohnstonElizabeth BasiliereDanyel OlsonChristopher D WilsonJasmine J WatkinsLauren Korhonen Dale N Gerding

Published in: Infection control and hospital epidemiology (2024)

Use of this 2-step algorithm likely results in underreporting of some NAAT+/toxin- cases with clinically relevant CDI. Disease severity and laboratory interpretive comments influence treatment decisions for NAAT+/toxin- cases.

Keyphrases

nucleic acid
escherichia coli
end stage renal disease
newly diagnosed
machine learning
ejection fraction
chronic kidney disease
clostridium difficile
prognostic factors
high throughput
genome wide
gene expression
risk assessment
single cell
replacement therapy